-
Molecular and Clinical Oncology Nov 2018Mucoepidermoid carcinoma of the anal canal is a rare tumor. We herein report the case of a 74-year-old male patient with a high-grade mucoepidermoid carcinoma of the...
Mucoepidermoid carcinoma of the anal canal is a rare tumor. We herein report the case of a 74-year-old male patient with a high-grade mucoepidermoid carcinoma of the anal canal who was treated by local surgical resection and subsequent irradiation. However, the patient succumbed to liver and lung metastases 2 years after the procedure. The characteristic findings of mucoepidermoid carcinoma of the anus remain unclear to date due to rarity of this tumor. Since 1954, when this type of tumor was first described, only 58 cases of patients diagnosed with mucoepidermoid carcinoma of the anus have been reported to date. In this context, a review of the existing English literature on this rare tumor was also performed.
PubMed: 30345043
DOI: 10.3892/mco.2018.1706 -
In Vivo (Athens, Greece) 2023To determine the interaction of gemcitabine in chemoradiotherapy with heavy carbon ions in vitro in a mucoepidermoid carcinoma (MEC) cell line.
BACKGROUND/AIM
To determine the interaction of gemcitabine in chemoradiotherapy with heavy carbon ions in vitro in a mucoepidermoid carcinoma (MEC) cell line.
MATERIALS AND METHODS
The human lymphatic MEC metastasis cell line NCI-H292 was used. The cells were treated with photons, carbon ions, and gemcitabine. Survival fractions (SF), apoptosis, and cell cycle progression were analyzed. A paired two-sided t-test was used. Significance was defined as p<0.05.
RESULTS
Cell proliferation assays showed a significant reduction in SF for combined photon chemoradiation versus photons only. The linear-quadratic fits of combined therapy with carbon ion dose of 0 to 2.5 Gy led to reductions of mean 15% in SF. The LD (lethal radiation dose required to reduce cell survival by 50%) for carbon ions only was 0.7 Gy and for carbon ions with gemcitabine 0.6 Gy. The LD for photons (with gemcitabine) was 2.8 Gy (2.0 Gy) and for carbon ions (with gemcitabine) 0.7 Gy (0.6 Gy), resulting in a relative biological effectiveness at 10% cell survival (RBE10) of 3.0 (2.7). Carbon ions and photons reduced S phase and increased G2/M phase cell distribution. Isolated treatment with gemcitabine as well as combination with photons led to prolonged S phase transit, whereas combined treatment with carbon ions led to early accumulation in G2/M phase. A significant increase in the sub-G1 population as a hint of relevant number of apoptotic cells was not observed.
CONCLUSION
Gemcitabine showed radiosensitizing effects in combination with photons. The combination of gemcitabine and carbon ions had independent additive effects. Carbon ions only had a RBE10 of 3.0, compared to photons only. The combination of gemcitabine, photon, and carbon ions in patients with MEC seems promising and warrants further investigation.
Topics: Humans; Gemcitabine; Deoxycytidine; Carcinoma, Mucoepidermoid; Cell Line, Tumor; Heavy Ion Radiotherapy; Chemoradiotherapy; Photons; Carbon; Ions
PubMed: 37652498
DOI: 10.21873/invivo.13291 -
Diagnostic Pathology Jan 2024Mammary mucoepidermoid carcinoma (MEC) is a rare entity. The molecular characteristics of breast MEC have not been fully investigated due to its rarity. We performed a...
Mammary mucoepidermoid carcinoma (MEC) is a rare entity. The molecular characteristics of breast MEC have not been fully investigated due to its rarity. We performed a retrospective study among 1000 patients with breast carcinomas and identified four cases of breast MEC. Clinical and demographic data were collected. Immunohistochemistry panels which were used to diagnose salivary gland MEC and breast carcinomas were also performed. MAML2 rearrangements were detected by FISH and fusion partners were identified by RNA sequencing. Whole-exome sequencing (WES) was used to reveal the genomes of these four breast MEC. Then, the biological functions and features of breast MEC were further compared with those of invasive breast carcinomas and salivary gland MEC.According to Ellis and Auclair's methods, these four breast MEC could be classified as low-grade breast MEC. All the patients were alive, and disease-free survival (PFS) ranged from 20 months to 67 months. Among these four breast MEC, two cases were triple-negative, and the other two cases were found to be ER positive, with one also showing HER2 equivocal by immunohistochemical staining, but no amplification in FISH. FISH analysis confirmed the presence of the MAML2 translocation in three of four tumors, and CRTC1-MAML2 fusion was confirmed in two of them by RNA-sequencing. The average coverage size of WES for the tumor mutation burden estimation was 32 Mb. MUC4, RP1L1 and QRICH2 mutations were identified in at least three tumors, and these mutation also existed in breast invasive carcinoma databases (TCGA, Cell 2015; TCGA, Nature 2012). The results showed that there were many genes in breast MEC overlapping with the breast invasive carcinoma databases mentioned above, range from 5 to 63 genes (median:21 genes). Next, we assessed immune cell infiltration levels in these tumors. In all these tumors, M2 macrophages and plasma cell were in the high infiltration group. Our breast MEC showed different results from the salivary gland MEC, whose plasma cells were in the low infiltration group. Overall, we first analyzed the genomics and tumor microenvironment of breast mucoepidermoid carcinoma and proposed our hypothesis that although MECs arising in the breast resemble their salivary gland counterparts phenotypically, our findings indicate that breast MECs probably resemble invasive breast carcinomas at the genetic level and immune cell infiltration levels. More cases and in deep research need to be done to further understand this rare carcinoma.
Topics: Humans; Female; DNA-Binding Proteins; Trans-Activators; Retrospective Studies; Carcinoma, Mucoepidermoid; Exome; Exome Sequencing; Tumor Microenvironment; Transcription Factors; Breast Neoplasms; Salivary Gland Neoplasms; Genomics; Sequence Analysis, RNA; Eye Proteins
PubMed: 38243319
DOI: 10.1186/s13000-024-01439-8 -
Clinical Case Reports Feb 2022Mucoepidermoid carcinoma (MEC) is an invasive tumor that has been reported in many organs, such as the salivary glands, lungs, esophagus, and thymus; however, it rarely...
Mucoepidermoid carcinoma (MEC) is an invasive tumor that has been reported in many organs, such as the salivary glands, lungs, esophagus, and thymus; however, it rarely affects the breast. Here, we report a case of primary breast MEC with imaging, including mammography, ultrasonography, and magnetic resonance imaging.
PubMed: 35169478
DOI: 10.1002/ccr3.5449 -
International Journal of Clinical and... 2015Pulmonary mucoepidermoid carcinoma (PMEC) is a rare malignant neoplasm with remarkable resemblance to mucoepidermoid carcinoma of the salivary glands. It constitutes a...
BACKGROUND
Pulmonary mucoepidermoid carcinoma (PMEC) is a rare malignant neoplasm with remarkable resemblance to mucoepidermoid carcinoma of the salivary glands. It constitutes a unique set of patient population. In this study we briefly discussed the current state of knowledge of PMEC and described the clinical presentation and management of 27 PMEC cases. This study aimed to discuss the utility of surgical treatment in the patients with pulmonary mucoepidermoid carcinoma.
METHODS
We retrospectively studied 27 cases with the diagnosis of PMEC, divided into low grade and high grade based on histopathological characteristics. The clinical symptoms, radiological manifestations, pathological characteristics, treatment strategy and prognosis were systemically analyzed.
RESULTS
The tumor could occur in any lobe of the lungs. The treatment included surgical intervention and/or adjuvant therapies. While the sex-age distribution and initial staging was not different between low- and high- grade PMEC, the disease control rate (95%) and 5 year survival (95%) were much higher in low-grade PMEC than the high-grade cases (57.1% and 42.9%, respectively).
CONCLUSION
The clinical, radiographical and pathological features of PMECs were systemically analyzed and summarized, and the utility of pathological grading system as the independent prognostic factor in addition to clinical staging was confirmed.
Topics: Adult; Aged; Asian People; Carcinoma, Mucoepidermoid; Female; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Retrospective Studies; Survival Analysis; Tomography, X-Ray Computed
PubMed: 26045810
DOI: No ID Found -
Medicine May 2023Mucoepidermoid carcinoma (MEC) is one of the most common malignant tumors in salivary glands, with specific histomorphological and molecular characteristics. MEC... (Review)
Review
RATIONALE
Mucoepidermoid carcinoma (MEC) is one of the most common malignant tumors in salivary glands, with specific histomorphological and molecular characteristics. MEC occurring in breast is more rare.
PATIENT CONCERNS
We reported 3 cases of female breast mass, diagnosed as benign nodules by ultrasound.
DIAGNOSES
The first 2 cases were pathological diagnosed as breast MEC, low grade, and the third case as breast MEC, medium grade.
INTERVENTIONS
After pathological diagnosis, 3 patients have expanded the scope of breast resection and lymph node dissection, with negative margin and no lymph node metastasis.
OUTCOMES
In the follow-up observation, the first case was followed up for 24 months, the second case was followed up for 30 months, and the third case was followed up for 12 months. All patients had a good prognosis without evidence of recurrence and metastasis.
CONCLUSION
Breast MEC is extremely rare and estrogen receptor, progesterone receptor, and human epidermal growth factor receptor-2 negative breast cancer with a good prognosis, which is different from other highly malignant triple-negative breast cancers. reviewed its clinicopathologic morphological characteristics, immunohistochemical markers and molecular characteristics, prognosis and clinical treatment through literature, in order to understanding its clinicopathology and providing reference for clinical precise treatment.
Topics: Humans; Female; Carcinoma, Mucoepidermoid; Prognosis; Salivary Glands; Breast Neoplasms; Lymphatic Metastasis
PubMed: 37144989
DOI: 10.1097/MD.0000000000033707 -
Ocular Oncology and Pathology Mar 2020The aim of this study was to assess whether mucoepidermoid carcinoma of the lacrimal sac is a counterpart of gene fusion-related salivary gland mucoepidermoid carcinoma.
PURPOSE
The aim of this study was to assess whether mucoepidermoid carcinoma of the lacrimal sac is a counterpart of gene fusion-related salivary gland mucoepidermoid carcinoma.
METHODS
In this retrospective observational case series, pathology records were searched for all cases of lacrimal sac mucoepidermoid carcinoma diagnosed between 1990 and 2018. Data collected included demographics, clinical findings, management, and follow-up. Pathologic parameters assessed included tumor morphology, immunohistochemistry, and and fluorescence in situ hybridization (FISH) studies.
RESULTS
Six patients with mucoepidermoid carcinoma of the lacrimal sac, 5 males and 1 female, with a median age of 63 years (range 24-66) were identified. Five tumors were managed with radical resection and 1 patient underwent orbital exenteration. None of the patients developed recurrence or metastases with an average follow-up of 18 months (range 13-23). All tumors had morphologic and immunohistochemical features of mucoepidermoid carcinoma and overexpressed EGFR. FISH was negative for rearrangement in all tumors. FISH demonstrated amplification in 1 tumor.
CONCLUSIONS
Mucoepidermoid carcinoma of the lacrimal sac is not a lacrimal sac counterpart of gene fusion-related salivary gland mucoepidermoid carcinoma. pathway activation and amplification in a subset of these neoplasms suggest the potential role for anti-EGFR agents.
PubMed: 32258022
DOI: 10.1159/000502699 -
Journal of Oral and Maxillofacial... 2022Mucoepidermoid Carcinoma (MEC) accounts for 10-15% of all salivary gland neoplasms and its management is related to tumour grading. The expression of mucin in the tumour...
CONTEXT
Mucoepidermoid Carcinoma (MEC) accounts for 10-15% of all salivary gland neoplasms and its management is related to tumour grading. The expression of mucin in the tumour cells presumably affects and predicts tumour behaviour.
AIMS
To analyse the expression of MUC1 (membrane bound mucin), MUC2 and MUC5AC (secreted mucins) in mucoepidermoid carcinoma and correlate with tumour grade and patient outcome.
SETTINGS AND DESIGN
In this retrospective correlation study the expression of MUC1, MUC2 and MUC5AC were investigated using immunohistochemistry in confirmed cases of MEC.
METHODS AND MATERIAL
The staining patterns of MUC1, MUC2 and MUC5AC were analysed in 10 confirmed cases from the year 2013 to 2020.
STATISTICAL ANALYSIS USED
SPSS 23 was used for bivariate correlations.
RESULTS
All of the tumours expressed MUC1, showing strong membranous to focal cytoplasmic localization in all cells. The goblet cell component expressed a strong apical membranous pattern. MUC2 expression was moderate, showed cytoplasmic localisation in 40% of mucinous cells and was minimal in intermediate cells and epidermoid cells. MUC 5AC expression was strong apical membranous in goblet cells and mainly negative in intermediate cells and epidermoid cells.
CONCLUSIONS
Although MUC1 is a reliable marker for all cell types of MEC but has no significant correlation with the tumour grade. MUC 2 has not been found to be a reliable diagnostic marker and has no significant correlation with the tumour grade. MUC 5AC has been found to have a significant expression in tumours with lymphoid infiltrate. There was no statistically significant correlation of MUC expression with the site, tumour grade and patient outcome.
PubMed: 36588842
DOI: 10.4103/jomfp.jomfp_342_21 -
Cureus Jan 2023Mucoepidermoid carcinoma is a common malignant neoplasm of the salivary glands. While quite common in the oral cavity, it is rare in the larynx. A middle-aged male...
Mucoepidermoid carcinoma is a common malignant neoplasm of the salivary glands. While quite common in the oral cavity, it is rare in the larynx. A middle-aged male patient presented to the otolaryngology clinic of our institution with the chief complaint of hoarseness. A supraglottic subepithelial mass was detected on the left laryngeal ventricle after a comprehensive clinical examination. Eventually, the diagnosis was established with a biopsy after a direct laryngoscopy. The multidisciplinary team of our institution suggested total laryngectomy without adjuvant modalities. An uneventful procedure followed and the patient remains free of disease and up to date. Mucoepidermoid tumors of the larynx are rare and surgical treatment is strongly indicated as the treatment of choice.
PubMed: 36874656
DOI: 10.7759/cureus.34455 -
Indian Journal of Otolaryngology and... Dec 2022Salivary gland tumours constitute an uncommon and diverse group of neoplasms that vary considerably in their histology and biologic behaviour. As per Globocon 2018,...
Salivary gland tumours constitute an uncommon and diverse group of neoplasms that vary considerably in their histology and biologic behaviour. As per Globocon 2018, salivary gland malignancy account for 0.3% of all cancer cases and 0.2% of all cancer deaths worldwide, reflecting the rarity of these neoplasms. Mucoepidermoid carcinoma (MEC) is a common malignant tumour of major and minor salivary gland, which comprises about 10% of all salivary gland neoplasms and approximately 35% of malignant salivary gland neoplasms. While three fourth of cases of MEC arise in the parotid, they account for a large proportion of salivary gland neoplasms occurring in minor salivary glands. Appending to the uncommonness, unusual presentations like MEC arising in heterotopic rests of salivary gland tissue in intraparotid or extraparotid lymph nodes, and MEC arising in lingual tonsils have been reported. Such diversity of clinical presentation may present a diagnostic challenge. In this continuum, we report a rare and unique case of low grade mucoepidermoid carcinoma of minor salivary gland, which primarily presented as cervical lymph node metastasis, three years before the primary intraoral lesion occurred.
PubMed: 36742659
DOI: 10.1007/s12070-021-02513-z